TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Tourmaline Bio ( (TRML) ).
Tourmaline Bio, Inc. announced amendments to its Executive Severance and Change in Control Plan, effective September 8, 2025. The changes enhance severance benefits for certain executives in the event of a change in control, impacting the company’s financial obligations and potentially its attractiveness to stakeholders.
The most recent analyst rating on (TRML) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Tourmaline Bio stock, see the TRML Stock Forecast page.
Spark’s Take on TRML Stock
According to Spark, TipRanks’ AI Analyst, TRML is a Neutral.
Tourmaline Bio’s overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company’s significant cash flow issues and lack of revenue growth.
To see Spark’s full report on TRML stock, click here.
More about Tourmaline Bio
Tourmaline Bio, Inc. operates in the biotechnology industry, focusing on developing innovative therapies and solutions to address unmet medical needs.
Average Trading Volume: 642,184
Technical Sentiment Signal: Buy
Current Market Cap: $1.22B
Learn more about TRML stock on TipRanks’ Stock Analysis page.